AZD9668
D0520C00012
Phase 2 small_molecule completed
Quick answer
AZD9668 for Chronic Obstructive Pulmonary Disease is a Phase 2 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- Chronic Obstructive Pulmonary Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed